PMID- 11242177
OWN - NLM
STAT- MEDLINE
DCOM- 20010405
LR  - 20200930
IS  - 1525-4135 (Print)
IS  - 1525-4135 (Linking)
VI  - 26
IP  - 2
DP  - 2001 Feb 1
TI  - In vitro effects of recombinant TNF-alpha binding protein (rTBP-1) on 
      hematopoiesis of HIV-infected patients.
PG  - 111-7
AB  - Tumor necrosis factor-alpha (TNF-alpha) is believed to contribute to the 
      hematopoietic failure often observed in patients with AIDS. Soluble TNF receptors 
      (sTNFR) compete for TNF-alpha with cell surface receptors and thus may block its 
      activity. The effect of the p55 sTNFR (recombinant TNF-binding protein-1 
      [rTBP-1]) on the clonogenic growth of hematopoietic progenitor cells from 27 
      HIV-infected patients was evaluated in comparison with 11 normal study subjects. 
      Peripheral blood-derived, myelopoietic (i.e., granulomonocytic colony-forming 
      cells [GM-CFC]) and erythropoietic (i.e, burst-forming unit, erythroid [BFU-E]) 
      colonies were grown in 10-day semisolid cultures with increasing concentrations 
      of rTBP-1. Significantly, dose-dependent increases occurred in GM-CFC from 17 of 
      21 AIDS patients and 12 of 21 in BFU-E at rTBP-1 concentrations of 1microg/ml to 
      25 microg/ml. In contrast, rTBP-1 failed to induce any appreciably increased 
      colony formation in normal cell cultures. In 6 patients treated with highly 
      active antiretroviral treatment (HAART), TBP-1 alone did not demonstrate the in 
      vitro hematopoiesis-enhancing effect. This study may provide an initial step in 
      development of therapeutic use of TBP as a TNF-alpha antagonist in HIV-infected 
      patients who do not benefit sufficiently from antiretroviral treatment, and in 
      other conditions in which increased levels of TNF-alpha may contribute to 
      hematopoietic deficiencies.
FAU - Gradstein, S
AU  - Gradstein S
AD  - Kaplan Medical Center, Rehovot, Israel.
FAU - Hahn, T
AU  - Hahn T
FAU - Barak, Y
AU  - Barak Y
FAU - Malach, L
AU  - Malach L
FAU - Revel, M
AU  - Revel M
FAU - Bentwich, Z
AU  - Bentwich Z
FAU - Handzel, Z T
AU  - Handzel ZT
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (Antigens, CD)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/immunology
MH  - Adult
MH  - Aged
MH  - Antigens, CD/*pharmacology
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Colony-Forming Units Assay
MH  - Dose-Response Relationship, Immunologic
MH  - Erythroid Precursor Cells/immunology
MH  - Female
MH  - Granulocytes/immunology
MH  - HIV Infections/*immunology
MH  - Hematopoiesis/*drug effects
MH  - Humans
MH  - In Vitro Techniques
MH  - Leukocytes, Mononuclear/drug effects/immunology
MH  - Male
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor
MH  - Receptors, Tumor Necrosis Factor, Type I
MH  - Recombinant Proteins/immunology
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 2001/03/10 10:00
MHDA- 2001/04/06 10:01
CRDT- 2001/03/10 10:00
PHST- 2001/03/10 10:00 [pubmed]
PHST- 2001/04/06 10:01 [medline]
PHST- 2001/03/10 10:00 [entrez]
AID - 10.1097/00042560-200102010-00002 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):111-7. doi: 
      10.1097/00042560-200102010-00002.